Acurx Pharmaceuticals
ACXP
26 hedge funds and large institutions have $1.15M invested in Acurx Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
567% more call options, than puts
Call options by funds: $20K | Put options by funds: $3K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
18% more funds holding
Funds holding: 22 → 26 (+4)
0.03% more ownership
Funds ownership: 0.39% → 0.42% (+0.03%)
52% less capital invested
Capital invested by funds: $2.41M → $1.15M (-$1.25M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$90.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$72.8K |
| 3 |
PFS
Prospect Financial Services
Melville,
New York
|
+$51.2K |
| 4 |
VF
Virtu Financial
New York
|
+$41.9K |
| 5 |
AA
ACT Advisors
Asheville,
North Carolina
|
+$32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$85.1K |
| 2 |
SG
StoneX Group
New York
|
-$33.8K |
| 3 |
NS
NBC Securities
Birmingham,
Alabama
|
-$28.6K |
| 4 |
TAM
Tocqueville Asset Management
New York
|
-$19K |
| 5 |
BlackRock
New York
|
-$3.94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NS
26
NBC Securities
Birmingham,
Alabama
| $15 | -$28.6K | -949 | -100% |
|
|
27
LPL Financial
San Diego,
California
| – | -$85.1K | -2,239 | Closed |
|
|
SG
28
StoneX Group
New York
| – | -$33.8K | -890 | Closed |
|
|
TAM
29
Tocqueville Asset Management
New York
| – | -$19K | -500 | Closed |
|
30
Simplex Trading
Chicago,
Illinois
| – | -$2K | -58 | Closed |
|
ACXP Hedge Fund Activity: Q4 2024 in Review
26 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q4 2024, worth a combined $1.15M — down 52% from $2.41M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ACXP positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $90.3K. The largest seller was LPL Financial, exiting entirely with an estimated $85.1K sold.
- 26 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q4 2024, up from 22 in Q3 2024.
- Funds reported $1.15M of Acurx Pharmaceuticals stock for Q4 2024, down 52% quarter-over-quarter.
- 8 funds opened new Acurx Pharmaceuticals positions in Q4 2024 and 4 closed out, a net change of +4 holders.
- The largest Acurx Pharmaceuticals buyer in Q4 2024 was Morgan Stanley, an estimated $90.3K added.
- The largest Acurx Pharmaceuticals seller in Q4 2024 was LPL Financial, an estimated $85.1K sold.
Based on aggregated 13F filings for Q4 2024.